Immunology

  1. A rapidly adaptable biomaterial vaccine for SARS-CoV-2

    1. Fernanda Langellotto
    2. Benjamin T. Seiler
    3. Jingyou Yu
    4. Mark J. Cartwright
    5. Des White
    6. Chyenne Yeager
    7. Michael Super
    8. Edward J. Doherty
    9. Dan H. Barouch
    10. David J. Mooney

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Animal Model Prescreening: Pre-exposure to SARS-CoV-2 impacts responses in the NHP model

    1. Keersten M. Ricks
    2. Andrew S. Herbert
    3. Jeffrey W. Koehler
    4. Paul A. Kuehnert
    5. Tamara L. Clements
    6. Charles J. Shoemaker
    7. Ana I. Kuehne
    8. Cecilia M. O’Brien
    9. Susan R. Coyne
    10. Korey L. Delp
    11. Kristen S. Akers
    12. John M. Dye
    13. Jay W. Hooper
    14. Jeffrey M. Smith
    15. Jeffrey R. Kugelman
    16. Brett F. Beitzel
    17. Kathleen M. Gibson
    18. Sara C. Johnston
    19. Timothy D. Minogue

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains

    1. Tongqing Zhou
    2. Yaroslav Tsybovsky
    3. Adam S. Olia
    4. Jason Gorman
    5. Micah A. Rapp
    6. Gabriele Cerutti
    7. Gwo-Yu Chuang
    8. Phinikoula S. Katsamba
    9. Alexandra Nazzari
    10. Jared M. Sampson
    11. Arne Schon
    12. Pengfei D. Wang
    13. Jude Bimela
    14. Wei Shi
    15. I-Ting Teng
    16. Baoshan Zhang
    17. Jeffrey C. Boyington
    18. Mallika Sastry
    19. Tyler Stephens
    20. Jonathan Stuckey
    21. Shuishu Wang
    22. Richard A. Friesner
    23. David D. Ho
    24. John R. Mascola
    25. Lawrence Shapiro
    26. Peter D. Kwong

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays

    1. Mei San Tang
    2. James Brett Case
    3. Caroline E Franks
    4. Rita E Chen
    5. Neil W Anderson
    6. Jeffrey P Henderson
    7. Michael S Diamond
    8. Ann M Gronowski
    9. Christopher W Farnsworth

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

    1. Flavia Chiuppesi
    2. Marcela d’Alincourt Salazar
    3. Heidi Contreras
    4. Vu H Nguyen
    5. Joy Martinez
    6. Soojin Park
    7. Jenny Nguyen
    8. Mindy Kha
    9. Angelina Iniguez
    10. Qiao Zhou
    11. Teodora Kaltcheva
    12. Roman Levytskyy
    13. Nancy D Ebelt
    14. Tae Hyuk Kang
    15. Xiwei Wu
    16. Thomas Rogers
    17. Edwin R Manuel
    18. Yuriy Shostak
    19. Don J Diamond
    20. Felix Wussow

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

    1. Alan Bénard
    2. Anne Jacobsen
    3. Maximilian Brunner
    4. Christian Krautz
    5. Bettina Klösch
    6. Izabela Swierzy
    7. Elisabeth Naschberger
    8. Malgorzata J. Podolska
    9. Dina Kouhestani
    10. Paul David
    11. Torsten Birkholz
    12. Ixchel Castellanos
    13. Denis Trufa
    14. Horia Sirbu
    15. Marcel Vetter
    16. Andreas E. Kremer
    17. Kai Hildner
    18. Andreas Hecker
    19. Fabian Edinger
    20. Matthias Tenbusch
    21. Petra Mühl-Zürbes
    22. Alexander Steinkasserer
    23. Enrico Richter
    24. Hendrik Streeck
    25. Marc M. Berger
    26. Thorsten Brenner
    27. Markus A. Weigand
    28. Filip K. Swirski
    29. Georg Schett
    30. Robert Grützmann
    31. Georg F. Weber

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis

    1. Onyeka S. Chukwudozie
    2. Rebecca C. Chukwuanukwu
    3. Onyekachi O. Iroanya
    4. Daniel M. Eze
    5. Vincent C. Duru
    6. Temiloluwa O. Dele-Alimi
    7. Busuyi D. Kehinde
    8. Taiwo T. Bankole
    9. Perpetua C. Obi
    10. Elizabeth U. Okinedo

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Early data on the performance of a combined SARS-CoV-2 spike-nucleocapsid antibody lateral flow immunoassay device compared with a nucleocapsid-only device

    1. Christian Linares
    2. Felicity Ryan
    3. Hannah Lowe
    4. Samuel Moses

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses

    1. Ulrik Stervbo
    2. Sven Rahmann
    3. Toralf Roch
    4. Timm H. Westhof
    5. Nina Babel

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies

    1. Priyamvada Acharya
    2. Wilton Williams
    3. Rory Henderson
    4. Katarzyna Janowska
    5. Kartik Manne
    6. Robert Parks
    7. Margaret Deyton
    8. Jordan Sprenz
    9. Victoria Stalls
    10. Megan Kopp
    11. Katayoun Mansouri
    12. Robert J Edwards
    13. R. Ryan Meyerhoff
    14. Thomas Oguin
    15. Gregory Sempowski
    16. Kevin Saunders
    17. Barton F. Haynes

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 30 of 170 Next